Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06303115 · ClinicalTrials.gov registry record · NA
CSD231005 Nicotine Pouch Biomarkers of Exposure
A NA study, sponsored by RAI Services Company.
- Completed
- Registry status
- NA
- Development phase
- 200
- Enrollment target
NCT06303115: Completed NA study, sponsored by RAI Services Company.
NCT06303115 is a NA study that has completed, run by RAI Services Company. The registered enrollment target is 200 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06303115, a NA study, has completed, sponsored by RAI Services Company.
- COMPLETED
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
Study Summary
This will be a multi center open label, randomized, controlled, switching parallel-group study designed to assess changes in select biomarkers of exposure (BoE) in generally healthy smokers following a 5 day in-clinic switch to use of nicotine Pouch investigational products (IPs) compared to continued usual brand (UB) cigarette smoking or smoking abstinence.
Interventions
- OTHER Nicotine Pouch P1312914, 4 mg nicotine
- OTHER Nicotine Pouch P1312915, 8 mg nicotine
- OTHER Nicotine Pouch P1013215, 8 mg nicotine
- OTHER Nicotine Pouch P1013218, 10 mg nicotine
- OTHER Nicotine Pouch P1012919, 12 mg nicotine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-08-22 |
| Est. Completion | 2025-01-15 |
| Phase | NA |
What the finished NCT06303115 record still lists
NCT06303115 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 5 interventions - of which Nicotine Pouch P1312914, 4 mg nicotine is the first listed.
NCT06303115 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06303115 about?
NCT06303115 is a clinical study titled "CSD231005 Nicotine Pouch Biomarkers of Exposure". This will be a multi center open label, randomized, controlled, switching parallel-group study designed to assess changes in select biomarkers of exposure (BoE) in generally healthy smokers following a 5 day in-clinic switch to use of nicotine Pouch investigational products (IPs) compared to continu...
What is the current status of trial NCT06303115?
This trial is currently completed. It is a NA study. The enrollment target is 200 participants. The study started on 2024-08-22. Estimated completion is 2025-01-15.
What interventions are being tested in trial NCT06303115?
The interventions under investigation include: Nicotine Pouch P1312914, 4 mg nicotine (OTHER), Nicotine Pouch P1312915, 8 mg nicotine (OTHER), Nicotine Pouch P1013215, 8 mg nicotine (OTHER), Nicotine Pouch P1013218, 10 mg nicotine (OTHER), Nicotine Pouch P1012919, 12 mg nicotine (OTHER).
Who is sponsoring clinical trial NCT06303115?
This trial is sponsored by RAI Services Company, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06303115's enrollment target sits among peer trials
200 506th of 2000 higher than 1,434 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI